# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Thibault Boutherin upgrades Alvotech (NASDAQ:ALVO) from Equal-Weight to Overweight and announces $14 ...
Advanz Pharma Holdco Limited ("Advanz Pharma"), a UK headquartered global pharmaceutical company with a strategic focus...
Deutsche Bank analyst Niall Alexander upgrades Alvotech (NASDAQ:ALVO) from Hold to Buy and announces $14 price target.
Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...
Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...
Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...